ANDA 79003, held by Watson Labs Teva. Ibandronate Sodium.
As of Nov 16, 2026, ANDA 79003 (Ibandronate Sodium), held by Watson Labs Teva, was first approved by FDA on Mar 20, 2012, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 150MG BASE · tablet;oral | Ibandronate Sodium | Discontinued |
| Feb 3, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 24, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 24, 2017 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 20, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters